LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after President Donald Trump dramatically cut global aid.
Trump administration touts moves to provide HIV prevention drug, but refuses to include South Africa
The US has started to provide doses of a Gilead HIV prevention drug to low-income countries, but the program will not include ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback